[go: up one dir, main page]

RU2015129468A - SYNTHETIC Glucopyranosyl lipid adjuvants - Google Patents

SYNTHETIC Glucopyranosyl lipid adjuvants Download PDF

Info

Publication number
RU2015129468A
RU2015129468A RU2015129468/04A RU2015129468A RU2015129468A RU 2015129468 A RU2015129468 A RU 2015129468A RU 2015129468/04 A RU2015129468/04 A RU 2015129468/04A RU 2015129468 A RU2015129468 A RU 2015129468A RU 2015129468 A RU2015129468 A RU 2015129468A
Authority
RU
Russia
Prior art keywords
compound
alkyl
gla
following formula
different
Prior art date
Application number
RU2015129468/04A
Other languages
Russian (ru)
Other versions
RU2015129468A3 (en
RU2732574C2 (en
Inventor
Стивен Дж. Рид
Даррик КАРТЕР
Original Assignee
Инфекшес Дизиз Рисерч Инститьют
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Инфекшес Дизиз Рисерч Инститьют filed Critical Инфекшес Дизиз Рисерч Инститьют
Publication of RU2015129468A publication Critical patent/RU2015129468A/en
Publication of RU2015129468A3 publication Critical patent/RU2015129468A3/ru
Application granted granted Critical
Publication of RU2732574C2 publication Critical patent/RU2732574C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C07H11/04—Phosphates; Phosphites; Polyphosphates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

1. Способ лечения инфекции, сезонного ринита, злокачественной опухоли, аутоиммунного заболевания, аллергии или астмы, включающий введение композиции, содержащей GLA (глюкопиранозиллипидный адъювант) соединение, имеющее следующую структуру (I):(I)или его фармацевтически приемлемая соль, где:L, L, L, L, Lи Lявляются одинаковыми или различными и независимо представляют собой -O- или -NH-;L, L, Lи Lявляются одинаковыми или различными и независимо отсутствуют или представляют собой -С(=O)-;Yпредставляет собой -OP(O)(OH);Y, Yи Yкаждый представляет -OH;R, R, Rи Rявляются одинаковыми или различными и независимо представляют собой Cалкил; иRи Rявляются одинаковыми или различными и независимо представляют собой Cалкил.2. Способ по п. 1, где Lи Lоба представляют собой -O-, а каждый из L, L, Lи Lпредставляет собой -C(=O)-, и GLA соединение имеет следующую формулу (II):(II)3. Способ по п. 2, где каждый из R, R, Rи Rпредставляет собой Cалкил, где x является постоянной и выбран из целых чисел от 8 до 13, а Rи Rоба представляют собой Cалкил, и GLA соединение имеет следующую формулу (III):(III)4. Способ по п. 3, где x выбирают из целых чисел от 10 до 12.5. Способ по п. 4, где x равен 11, и GLA соединение имеет следующую структуру (IV):(IV)6. Способ по п. 2, где Lи Lоба представляют собой -O-, аLи Lоба представляют собой -NH-, и GLA соединение имеет следующую формулу (VI):(VI)7. Способ по п. 2, где Yпредставляет собой -OP(O)(OH), каждый из Y, Yи Yпредставляет собой -OH, Lи Lоба представляют собой -O-, и Lи Lоба представляют собой -NH-, и GLA соединение имеет следующую формулу (VII):(VII)8. Способ по п. 2, где Yпредставляет собой -OP(O)(OH), каждый из Y, Yи Yпредставляет собой -OH, Lи Lпредставляют собой -O-, Lи Lоба представляют собой -NH-, каждый из R, R, Rи Rпредставляет собо�1. A method of treating an infection, seasonal rhinitis, malignant tumor, autoimmune disease, allergy or asthma, comprising administering a composition comprising a GLA (glucopyranosyl lipid adjuvant) compound having the following structure (I) :( I) or a pharmaceutically acceptable salt thereof, where: L , L, L, L, L, and L are the same or different and independently are —O— or —NH—; L, L, L and L are the same or different and are independently absent or are — C (= O) -; Y is - OP (O) (OH); Y, Y, and Y each represent —OH; R, R, R, and R are one tical or different and independently represent Ci ^ alkyl; and R and R are the same or different and independently represent C1-6alkyl. 2. The method of claim 1, wherein L and Loba are —O—, and each of L, L, L and L is —C (= O) -, and the GLA compound has the following formula (II): (II) 3. The method of claim 2, wherein each of R, R, R and R is C 1-6 alkyl, where x is constant and selected from integers from 8 to 13, and R and R 2 are C 1-6 alkyl, and the GLA compound has the following formula (III): ( III) 4. The method of claim 3, wherein x is selected from integers from 10 to 12.5. The method of claim 4, wherein x is 11 and the GLA compound has the following structure (IV) :( IV) 6. The method of claim 2, wherein L and Loba are —O—, and L and Loba are —NH—, and the GLA compound has the following formula (VI): (VI) 7. The method of claim 2, wherein Y is —OP (O) (OH), each of Y, Y, and Y is —OH, L and Loba are —O—, and L and Loba are —NH—, and the GLA compound has the following formula (VII) :( VII) 8. The method of claim 2, wherein Y is —OP (O) (OH), each of Y, Y, and Y is —OH, L and L are —O—, L and L are both —NH—, each of R, R, R and R represents

Claims (11)

1. Способ лечения инфекции, сезонного ринита, злокачественной опухоли, аутоиммунного заболевания, аллергии или астмы, включающий введение композиции, содержащей GLA (глюкопиранозиллипидный адъювант) соединение, имеющее следующую структуру (I):1. A method of treating an infection, seasonal rhinitis, a malignant tumor, an autoimmune disease, allergy or asthma, comprising administering a composition containing a GLA (glucopyranosyl lipid adjuvant) compound having the following structure (I):
Figure 00000001
(I)
Figure 00000001
(I) или его фармацевтически приемлемая соль, где:or its pharmaceutically acceptable salt, where: L1, L2, L3, L4, L5 и L6 являются одинаковыми или различными и независимо представляют собой -O- или -NH-;L 1 , L 2 , L 3 , L 4 , L 5 and L 6 are the same or different and independently represent —O— or —NH—; L7, L8, L9 и L10 являются одинаковыми или различными и независимо отсутствуют или представляют собой -С(=O)-;L 7 , L 8 , L 9 and L 10 are the same or different and are independently absent or are —C (═O) -; Y1 представляет собой -OP(O)(OH)2;Y 1 represents —OP (O) (OH) 2 ; Y2, Y3 и Y4 каждый представляет -OH;Y 2 , Y 3 and Y 4 each represents —OH; R1, R3, R5 и R6 являются одинаковыми или различными и независимо представляют собой C8-13алкил; иR 1 , R 3 , R 5 and R 6 are the same or different and independently represent C 8-13 alkyl; and R2 и R4 являются одинаковыми или различными и независимо представляют собой C6-11алкил.R 2 and R 4 are the same or different and independently represent C 6-11 alkyl. 2. Способ по п. 1, где L5 и L6 оба представляют собой -O-, а каждый из L7, L8, L9 и L10 представляет собой -C(=O)-, и GLA соединение имеет следующую формулу (II):2. The method of claim 1, wherein L 5 and L 6 are both —O— and each of L 7 , L 8 , L 9 and L 10 is —C (= O) -, and the GLA compound has the following formula (II):
Figure 00000002
(II)
Figure 00000002
(Ii) 3. Способ по п. 2, где каждый из R1, R3, R5 и R6 представляет собой Cxалкил, где x является постоянной и выбран из целых чисел от 8 до 13, а R2 и R4 оба представляют собой Cx-2алкил, и GLA соединение имеет следующую формулу (III):3. The method according to claim 2, where each of R 1 , R 3 , R 5 and R 6 is C x alkyl, where x is constant and selected from integers from 8 to 13, and R 2 and R 4 both represent C x-2 alkyl, and the GLA compound has the following formula (III):
Figure 00000003
(III)
Figure 00000003
(III) 4. Способ по п. 3, где x выбирают из целых чисел от 10 до 12.4. The method according to p. 3, where x is selected from integers from 10 to 12. 5. Способ по п. 4, где x равен 11, и GLA соединение имеет следующую структуру (IV):5. The method according to p. 4, where x is equal to 11, and the GLA compound has the following structure (IV):
Figure 00000004
(IV)
Figure 00000004
(Iv) 6. Способ по п. 2, где L1 и L3 оба представляют собой -O-, а 6. The method of claim 2, wherein L 1 and L 3 are both —O—, and L2 и L4 оба представляют собой -NH-, и GLA соединение имеет следующую формулу (VI):L 2 and L 4 are both —NH— and the GLA compound has the following formula (VI):
Figure 00000005
(VI)
Figure 00000005
(Vi) 7. Способ по п. 2, где Y1 представляет собой -OP(O)(OH)2, каждый из Y2, Y3 и Y4 представляет собой -OH, L1 и L3 оба представляют собой -O-, и L2 и L4 оба представляют собой -NH-, и GLA соединение имеет следующую формулу (VII):7. The method of claim 2, wherein Y 1 is —OP (O) (OH) 2 , each of Y 2 , Y 3, and Y 4 is —OH, L 1 and L 3 are both —O—, and L 2 and L 4 are both —NH—, and the GLA compound has the following formula (VII):
Figure 00000006
(VII)
Figure 00000006
(Vii) 8. Способ по п. 2, где Y1 представляет собой -OP(O)(OH)2, каждый из Y2, Y3 и Y4 представляет собой -OH, L1 и L3 представляют собой -O-, L2 и L4 оба представляют собой -NH-, каждый из R1, R3, R5 и R6 представляет собой Cxалкил, где x является постоянной и выбирают из целых чисел от 8 до 13, и R2 и R4 оба представляют собой Cx-2алкил, и GLA соединение имеет следующую формулу (VIII):8. The method of claim 2, wherein Y 1 is —OP (O) (OH) 2 , each of Y 2 , Y 3, and Y 4 is —OH, L 1 and L 3 are —O—, L 2 and L 4 are both —NH—, each of R 1 , R 3 , R 5 and R 6 is C x alkyl, where x is constant and selected from integers from 8 to 13, and R 2 and R 4 both are C x-2 alkyl, and the GLA compound has the following formula (VIII):
Figure 00000007
(VIII)
Figure 00000007
(Viii) 9. Способ лечения инфекции, злокачественной опухоли, аутоиммунного заболевания, аллергии или астмы, включающий введение композиции, содержащей соединение, имеющее следующую структуру (IX), или его фармацевтически приемлемую соль:9. A method for treating an infection, cancer, autoimmune disease, allergy or asthma, comprising administering a composition containing a compound having the following structure (IX), or a pharmaceutically acceptable salt thereof:
Figure 00000008
(IX)
Figure 00000008
(Ix) 10. Способ по любому из пп. 1-9, где композиция по существу свободна от антигенов.10. The method according to any one of paragraphs. 1-9, where the composition is essentially free of antigens. 11. Способ по любому из пп. 1-9, где композиция дополнительно содержит антиген или рекомбинантный экспрессирующий вектор, кодирующий антиген. 11. The method according to any one of paragraphs. 1-9, where the composition further comprises an antigen or recombinant expression vector encoding an antigen.
RU2015129468A 2009-06-05 2010-06-04 Synthetic glucopyranosyl lipoid adjuvants RU2732574C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18470309P 2009-06-05 2009-06-05
US61/184,703 2009-06-05

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2011152602/04A Division RU2560182C2 (en) 2009-06-05 2010-06-04 Synthetic glucopyranosyllipid adjuvants

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2020129844A Division RU2020129844A (en) 2009-06-05 2020-09-10 SYNTHETIC GLUCOPYRANOSILLIPID ADJUVANTS

Publications (3)

Publication Number Publication Date
RU2015129468A true RU2015129468A (en) 2015-12-27
RU2015129468A3 RU2015129468A3 (en) 2019-01-21
RU2732574C2 RU2732574C2 (en) 2020-09-21

Family

ID=43298190

Family Applications (3)

Application Number Title Priority Date Filing Date
RU2015129468A RU2732574C2 (en) 2009-06-05 2010-06-04 Synthetic glucopyranosyl lipoid adjuvants
RU2011152602/04A RU2560182C2 (en) 2009-06-05 2010-06-04 Synthetic glucopyranosyllipid adjuvants
RU2020129844A RU2020129844A (en) 2009-06-05 2020-09-10 SYNTHETIC GLUCOPYRANOSILLIPID ADJUVANTS

Family Applications After (2)

Application Number Title Priority Date Filing Date
RU2011152602/04A RU2560182C2 (en) 2009-06-05 2010-06-04 Synthetic glucopyranosyllipid adjuvants
RU2020129844A RU2020129844A (en) 2009-06-05 2020-09-10 SYNTHETIC GLUCOPYRANOSILLIPID ADJUVANTS

Country Status (22)

Country Link
US (4) US8722064B2 (en)
EP (2) EP2437753B1 (en)
JP (3) JP5830015B2 (en)
CN (2) CN102481312B (en)
AU (1) AU2010256461B2 (en)
BR (1) BRPI1011072B1 (en)
CA (1) CA2764374C (en)
CY (1) CY1118347T1 (en)
DK (1) DK2437753T3 (en)
ES (1) ES2606563T3 (en)
HR (1) HRP20161585T1 (en)
HU (1) HUE031051T2 (en)
IL (2) IL216669A (en)
LT (1) LT2437753T (en)
MX (3) MX393384B (en)
PL (1) PL2437753T3 (en)
PT (1) PT2437753T (en)
RU (3) RU2732574C2 (en)
SI (1) SI2437753T1 (en)
SM (1) SMT201600437B (en)
TW (2) TWI494125B (en)
WO (1) WO2010141861A1 (en)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
FI2068918T4 (en) 2006-09-26 2024-08-16 Access To Advanced Health Inst Vaccine composition containing synthetic adjuvant
CN102282155B (en) 2008-12-02 2017-06-09 日本波涛生命科学公司 The synthetic method of the nucleic acid of phosphorus atoms modification
PT2437753T (en) 2009-06-05 2016-11-23 Infectious Disease Res Inst Synthetic glucopyranosyl lipid adjuvants and vaccine compositions containing them
CA2767253A1 (en) 2009-07-06 2011-01-13 Ontorii, Inc. Novel nucleic acid prodrugs and methods of use thereof
US20110305748A1 (en) 2010-03-11 2011-12-15 Immune Design, Corp. Vaccines for Pandemic Influenza
DK2620428T3 (en) 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetric help group
WO2012112691A1 (en) 2011-02-15 2012-08-23 Immune Design Corp. Methods for enhancing immunogen specific immune responses by vectored vaccines
NZ616304A (en) 2011-04-08 2016-01-29 Immune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
US20120288515A1 (en) 2011-04-27 2012-11-15 Immune Design Corp. Synthetic long peptide (slp)-based vaccines
JP6128529B2 (en) 2011-07-19 2017-05-17 ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． Methods for the synthesis of functionalized nucleic acids
WO2013072768A2 (en) 2011-11-18 2013-05-23 Variation Biotechnologies, Inc. Synthetic derivatives of mpl and uses thereof
EP3984551A1 (en) 2011-12-02 2022-04-20 Rhode Island Hospital Vaccine for falciparum malaria
WO2013119856A1 (en) 2012-02-07 2013-08-15 Infectious Disease Research Institute Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
JP5650780B2 (en) * 2012-04-04 2015-01-07 日東電工株式会社 Vaccine composition
BR112014028476A2 (en) 2012-05-16 2017-08-01 Immune Design Corp immunogenic fragment of a polypeptide, isolated polynucleotide, immunogenic pharmaceutical composition, methods for treating an infection, for generating an immune response in a subject, and for immunizing a subject
KR20150022996A (en) 2012-06-08 2015-03-04 아두로 바이오테크 Compositions and methods for cancer immunotherapy
KR101850319B1 (en) 2012-07-13 2018-04-20 웨이브 라이프 사이언시스 리미티드 Asymmetric auxiliary group
CN112007045A (en) 2012-07-13 2020-12-01 波涛生命科学有限公司 Chiral control
SG11201500243WA (en) * 2012-07-13 2015-04-29 Shin Nippon Biomedical Lab Ltd Chiral nucleic acid adjuvant
KR20150095668A (en) 2012-12-13 2015-08-21 아두로 바이오테크, 인코포레이티드 Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
WO2014172637A1 (en) 2013-04-18 2014-10-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
ES2982836T3 (en) 2013-04-29 2024-10-17 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
EP2992000B1 (en) 2013-05-03 2020-07-08 The Regents of The University of California Cyclic di-nucleotide induction of type i interferon
SMT201900635T1 (en) 2013-05-18 2020-01-14 Univ California Compositions and methods for activating
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
US9463198B2 (en) * 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
WO2015017652A1 (en) 2013-07-31 2015-02-05 Memorial Sloan-Kettering Cancer Center Sting crystals and modulators
WO2015035010A1 (en) * 2013-09-05 2015-03-12 Immune Design Corp. Vaccine compositions for drug addiction
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9017698B2 (en) 2013-09-25 2015-04-28 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
BR112016006245A2 (en) 2013-10-03 2017-08-01 Nitto Denko Corp mucosal vaccine composition
TW201601750A (en) 2013-10-03 2016-01-16 Nitto Denko Corp Injectable vaccine composition
CA2923026A1 (en) 2013-10-03 2015-04-09 Nitto Denko Corporation Nasal mucosal vaccine composition
AU2014330336A1 (en) 2013-10-03 2016-03-17 Nitto Denko Corporation Mucosal vaccine composition
BR112016015422A2 (en) 2013-12-31 2017-10-24 Infectious Disease Res Inst single vial vaccine formulations
EP3095461A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
JPWO2015108046A1 (en) 2014-01-15 2017-03-23 株式会社新日本科学 Chiral nucleic acid adjuvant and antiallergic agent having antiallergic action
WO2015108048A1 (en) 2014-01-15 2015-07-23 株式会社新日本科学 Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
EP4137572A1 (en) 2014-01-16 2023-02-22 Wave Life Sciences Ltd. Chiral design
AU2015209575A1 (en) * 2014-01-21 2016-07-21 Immune Design Corp. Compositions for use in the treatment of allergic conditions
SG11201606625RA (en) 2014-02-14 2016-09-29 Immune Design Corp Immunotherapy of cancer through combination of local and systemic immune stimulation
CA2955015A1 (en) 2014-07-15 2016-01-21 Immune Design Corp. Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
PE20171448A1 (en) 2015-03-10 2017-10-02 Aduro Biotech Inc COMPOSITIONS AND METHODS FOR ACTIVATING SIGNALING DEPENDENT ON THE INTERFERON GENE STIMULATOR
EP3381467A4 (en) 2015-11-27 2019-06-05 Nitto Denko Corporation Vaccine pharmaceutical composition for oral administration and method for manufacturing vaccine pharmaceutical composition for oral administration
IL319503A (en) 2016-05-16 2025-05-01 Access To Advanced Health Inst Pegylated liposomes and methods of use
CA3023968A1 (en) 2016-05-16 2017-11-23 Infectious Disease Research Institute Formulation containing tlr agonist and methods of use
KR20190009308A (en) 2016-05-21 2019-01-28 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) Compositions and methods for treating secondary tuberculosis and non-tuberculous mycobacterial infections
IL315825A (en) 2016-06-01 2024-11-01 Access To Advanced Health Inst Nanoalum particles containing a sizing agent
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
US11633411B2 (en) 2016-10-04 2023-04-25 University Of Maryland, Baltimore Methods of treating sepsis using anti-sepsis lipid A (ASLA) based therapeutics
US10874734B2 (en) * 2016-11-25 2020-12-29 Mogam Institute For Biomedical Research Varicella zoster virus vaccine
EP3560512A4 (en) 2016-12-26 2020-07-22 Mogam Institute for Biomedical Research HERPES-ZOSTER VACCINE COMPOSITION
UY37695A (en) 2017-04-28 2018-11-30 Novartis Ag BIS 2’-5’-RR- (3’F-A) (3’F-A) CYCLE DINUCLEOTIDE COMPOUND AND USES OF THE SAME
IL271384B2 (en) 2017-06-15 2025-02-01 Access To Advanced Health Inst Nanostructured lipid carriers and stable emulsions and uses thereof
JP7339942B2 (en) * 2017-09-08 2023-09-06 アクセス ツー アドバンスト ヘルス インスティチュート Liposomal formulation containing saponin and method of use
JP2020533354A (en) 2017-09-13 2020-11-19 サノフィ・パスツールＳａｎｏｆｉ Ｐａｓｔｅｕｒ Human cytomegalovirus immunogenic composition
MX2020008417A (en) 2018-02-12 2020-11-11 Inimmune Corp Toll-like receptor ligands.
US20190275134A1 (en) 2018-03-12 2019-09-12 Janssen Pharmaceuticals, Inc Vaccines against urinary tract infections
WO2020109365A1 (en) * 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
PL3942028T3 (en) 2019-03-18 2023-10-23 Janssen Pharmaceuticals, Inc. Methods of producing bioconjugates of e. coli o-antigen polysaccharides, compositions thereof, and methods of use thereof
SG11202110301TA (en) 2019-03-18 2021-10-28 Janssen Pharmaceuticals Inc Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
WO2020243115A1 (en) 2019-05-25 2020-12-03 Infectious Disease Research Institute Composition and method for spray drying an adjuvant vaccine emulsion
WO2021194672A1 (en) 2020-03-23 2021-09-30 Hdt Bio Corp. Compositions and methods for delivery of rna
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
EP4038091A1 (en) 2019-10-02 2022-08-10 Janssen Vaccines & Prevention B.V. Staphylococcus peptides and methods of use
US20220396797A1 (en) 2019-11-15 2022-12-15 Infectious Disease Research Institute Rig-i agonist and adjuvant formulation for tumor treatment
HUE068985T2 (en) 2020-01-16 2025-02-28 Janssen Pharmaceuticals Inc Fimh mutant, compositions therewith and use thereof
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
CA3174411A1 (en) 2020-09-04 2022-03-10 Ryan M. Kramer Co-lyophilized rna and nanostructured lipid carrier
AU2021342797B2 (en) 2020-09-17 2024-02-08 Janssen Pharmaceuticals, Inc. Multivalent vaccine compositions and uses thereof
CA3200234A1 (en) 2020-11-25 2022-06-02 Daryl C. Drummond Lipid nanoparticles for delivery of nucleic acids, and related methods of use
AU2021406131A1 (en) 2020-12-23 2023-08-03 Access To Advanced Health Institute Solanesol vaccine adjuvants and methods of preparing same
WO2022153166A1 (en) 2021-01-12 2022-07-21 Janssen Pharmaceuticals, Inc. Fimh mutants, compositions therewith and use thereof
CN117222427A (en) 2021-04-01 2023-12-12 杨森制药公司 Production of E.coli O18 bioconjugates
WO2022256740A1 (en) 2021-06-04 2022-12-08 Curia Ip Holdings, Llc Polymeric fusion proteins and compositions for inducing an immune response against infection
JP2024535353A (en) 2021-09-22 2024-09-30 エイチディーティー バイオ コーポレーション RNA vaccines against infectious diseases
JP2024535352A (en) 2021-09-22 2024-09-30 エイチディーティー バイオ コーポレーション SARS-COV-2 RNA VACCINE COMPOSITIONS AND METHODS OF USE
JP2024535351A (en) 2021-09-22 2024-09-30 エイチディーティー バイオ コーポレーション Dry Nanoparticle Composition
CN117105888A (en) * 2022-05-17 2023-11-24 北京科兴中维生物技术有限公司 A kind of synthesis method of MPLA acyl chain intermediate
KR20250031230A (en) 2022-05-25 2025-03-06 아카제라 메디신즈, 인크. Lipid nanoparticles for nucleic acid delivery and methods of using the same

Family Cites Families (242)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3238190A (en) 1963-10-23 1966-03-01 Madaus & Co K G Fa Dr Aescin recovery
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4029762A (en) * 1971-11-17 1977-06-14 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Lipid A-preparation
US4286592A (en) 1980-02-04 1981-09-01 Alza Corporation Therapeutic system for administering drugs to the skin
US4314557A (en) 1980-05-19 1982-02-09 Alza Corporation Dissolution controlled active agent dispenser
US4420558A (en) 1981-02-12 1983-12-13 Janssen Pharmaceutica N.V. Bright field light microscopic method of enumerating and characterizing subtypes of white blood cells and their precursors
US4379454A (en) 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4420461A (en) 1982-05-26 1983-12-13 Ortho Diagnostic Systems Inc. Agglutination-inhibition test kit for detecting immune complexes
SE8205892D0 (en) 1982-10-18 1982-10-18 Bror Morein IMMUNOGENT MEMBRANE PROTEIN COMPLEX, SET FOR PREPARATION AND USE THEREOF
US4987237A (en) * 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US4743540A (en) 1983-09-27 1988-05-10 Memorial Sloan-Kettering Cancer Center Method for diagnosis of subclassifications of common varied immunodeficiency disease group
US5147785A (en) 1983-11-01 1992-09-15 Amtl Corporation Method and apparatus for measuring the degree of reaction between a foreign entity and white blood cells
US4614722A (en) 1983-11-01 1986-09-30 Pasula Mark J Method and apparatus for measuring the degree of reaction between antigens and leukocyte cellular antibodies
US4595654A (en) 1983-11-07 1986-06-17 Immunomedics Inc. Method for detecting immune complexes in serum
US4855238A (en) 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
US4629722A (en) 1984-07-12 1986-12-16 Ribi Immunochem Research, Inc. Method of inhibiting the onset of acute radiation syndrome
US4844894A (en) * 1984-07-12 1989-07-04 Ribi Immunochem Research Inc. Method of inhibiting the onset of septicemia and endotoxemia
US5612041A (en) * 1984-07-17 1997-03-18 Chiron Corporation Recombinant herpes simplex gD vaccine
US5066794A (en) * 1984-08-24 1991-11-19 Daiichi Pharmaceutical Co., Ltd. Process for preparing a disaccharide derivative
JPS6153295A (en) * 1984-08-24 1986-03-17 Dai Ichi Seiyaku Co Ltd Disaccharide derivative
US4568343A (en) 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US4659659A (en) 1985-01-22 1987-04-21 Monsanto Company Diagnostic method for diseases having an arthritic component
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
FI861417A0 (en) 1985-04-15 1986-04-01 Endotronics Inc HEPATITIS B YTANTIGEN FRAMSTAELLD MED REKOMBINANT-DNA-TEKNIK, VACCIN, DIAGNOSTISKT MEDEL OCH CELLINJER SAMT FOERFARANDEN FOER FRAMSTAELLNING DAERAV.
US4746742A (en) 1985-11-28 1988-05-24 Toho Yakuhin Kogyo Kabushiki Kaisha Analogs of nonreducing monosaccharide moiety of lipid A
US6544728B1 (en) * 1986-01-22 2003-04-08 Institut Pasteur Methods and kits for diagnosing human immunodeficiency virus type 2 (HIV-2), proteins of HIV-2, and vaccinating agents for HIV-2
US5310651A (en) 1986-01-22 1994-05-10 Institut Pasteur DNA probes of human immunodeficiency virus type 2 (HIV-2), and methods employing these probes for dectecting the presence of HIV-2
US6514691B1 (en) 1986-01-22 2003-02-04 Institut Pasteur Peptides of human immunodeficiency virus type 2 (HIV-2), antibodies against peptides of HIV-2, and methods and kits for detecting HIV-2
US6054565A (en) * 1986-03-03 2000-04-25 Institut Pasteur Nucleic Acids of HIV-2, Diagnostic Test Kit and Method using Nucleic Acid Probes of HIV-2
US5169763A (en) 1986-04-08 1992-12-08 Transgene S.A., Institut Pasteur Viral vector coding glycoprotein of HIV-1
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
JPH0755906B2 (en) 1986-07-01 1995-06-14 第一製薬株式会社 Analgesic containing disaturated derivative
US4948587A (en) 1986-07-08 1990-08-14 Massachusetts Institute Of Technology Ultrasound enhancement of transbuccal drug delivery
US4767402A (en) 1986-07-08 1988-08-30 Massachusetts Institute Of Technology Ultrasound enhancement of transdermal drug delivery
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
FR2672290B1 (en) 1991-02-05 1995-04-21 Pasteur Institut SPECIFIC PEPTIDE SEQUENCES OF THE HEPATIC STAGES OF P. FALCIPARUM CARRIERS OF EPITOPES CAPABLE OF STIMULATING T-LYMPHOCYTES
US5565209A (en) 1987-03-17 1996-10-15 Akzo Nobel N.V. Adjuvant mixture
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
EP1088830A3 (en) 1987-06-22 2004-04-07 Medeva Holdings B.V. Hepatitis b surface antigen particles
US4780212A (en) 1987-07-31 1988-10-25 Massachusetts Institute Of Technology Ultrasound enchancement of membrane permeability
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
EP0324455A3 (en) 1988-01-15 1991-03-27 Hans O. Ribi Novel polymeric immunological adjuvants
GB2232892B (en) 1988-02-23 1991-07-24 John Mark Tucker Occlusive body for administering a physiologically active substance
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5888519A (en) 1988-06-02 1999-03-30 The United States Of America As Represented By The Secretary Of The Army Encapsulated high-concentration lipid a compositions as immunogenic agents to produce human antibodies to prevent or treat gram-negative bacterial infections
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB8819209D0 (en) 1988-08-12 1988-09-14 Research Corp Ltd Polypeptide & dna encoding same
US5231168A (en) * 1988-09-16 1993-07-27 Statens Seruminstitut Malaria antigen
US4999403A (en) 1988-10-28 1991-03-12 Exxon Chemical Patents Inc. Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions
ATE205534T1 (en) 1988-12-16 2001-09-15 Nederlanden Staat PNEUMOLYSINE MUTANTS AND PNEUMOCOCCAL VACCINES THEREOF
EP0454781B1 (en) 1989-01-23 1998-12-16 Chiron Corporation Recombinant cells for therapies of infection and hyperproliferative disorders and preparation thereof
DK0382271T3 (en) * 1989-02-04 1995-05-01 Akzo Nobel Nv Tocoler as adjuvants in vaccines
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
FR2649013B1 (en) * 1989-07-03 1991-10-25 Seppic Sa VACCINES AND VECTORS OF FLUID ACTIVE INGREDIENTS CONTAINING METABOLIZABLE OIL
FR2649012B1 (en) 1989-07-03 1991-10-25 Seppic Sa INJECTABLE MULTIPHASIC EMULSIONS
DE69031556T2 (en) 1989-07-25 1998-05-14 Smithkline Beecham Biologicals S.A., Rixensart Antigens and processes for their production
EP0487587A1 (en) 1989-08-18 1992-06-03 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
US4981684A (en) * 1989-10-24 1991-01-01 Coopers Animal Health Limited Formation of adjuvant complexes
US6120769A (en) 1989-11-03 2000-09-19 Immulogic Pharmaceutical Corporation Human T cell reactive feline protein (TRFP) isolated from house dust and uses therefor
US5298396A (en) * 1989-11-15 1994-03-29 National Jewish Center For Immunology And Respiratory Medicine Method for identifying T cells disease involved in autoimmune disease
US5256643A (en) 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein
US5124141A (en) 1990-06-14 1992-06-23 Flow Incorporated Method for diagnosing malaria
US5162990A (en) 1990-06-15 1992-11-10 The United States Of America As Represented By The United States Navy System and method for quantifying macrophage phagocytosis by computer image analysis
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
ATE356142T1 (en) 1991-07-19 2007-03-15 Univ Queensland VACCINE AGAINST HUMAN PAPILLOMAVIRUS (TYPE 18)
US5464387A (en) 1991-07-24 1995-11-07 Alza Corporation Transdermal delivery device
DK0596032T4 (en) 1991-07-25 2004-07-26 Idec Pharma Corp Induction of cytotoxic T lymphocyte responses
US6197311B1 (en) * 1991-07-25 2001-03-06 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
ATE132742T1 (en) 1991-08-16 1996-01-15 Vical Inc COMPOSITION AND METHOD FOR TREATING CYSTIC FIBROSIS
US5530113A (en) * 1991-10-11 1996-06-25 Eisai Co., Ltd. Anti-endotoxin compounds
AU660325B2 (en) 1991-10-11 1995-06-22 Eisai Co. Ltd. Anti-endotoxin compounds and related molecules and methods
JP3954643B2 (en) 1991-11-16 2007-08-08 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム Hybrid protein between CS and HBsAG derived from Plasmodium
US6057427A (en) * 1991-11-20 2000-05-02 Trustees Of Dartmouth College Antibody to cytokine response gene 2(CR2) polypeptide
CA2085827C (en) 1991-12-23 2003-10-14 Lucas A. T. Hilgers Adjuvant composition containing synthetic hydrophobic lipopolysaccharide
US5286718A (en) 1991-12-31 1994-02-15 Ribi Immunochem Research, Inc. Method and composition for ameliorating tissue damage due to ischemia and reperfusion
JPH05328975A (en) 1992-06-02 1993-12-14 Takara Shuzo Co Ltd E1a-f gene
WO1993025234A1 (en) 1992-06-08 1993-12-23 The Regents Of The University Of California Methods and compositions for targeting specific tissue
WO1993025698A1 (en) 1992-06-10 1993-12-23 The United States Government As Represented By The Vector particles resistant to inactivation by human serum
DE122007000094I1 (en) 1992-06-25 2008-03-27 PAPILLOMA VIRUS VACCINE
PT761231E (en) 1992-06-25 2000-06-30 Smithkline Beecham Biolog COMPOSITION OF VACCINES CONTAINING ADJUVANTES
US5786148A (en) 1996-11-05 1998-07-28 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a novel prostate-specific kallikrein
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5411865A (en) * 1993-01-15 1995-05-02 Iasys Corporation Method of detecting anti-leishmania parasite antibodies
AU688759C (en) 1993-03-09 2006-12-21 University Of Rochester Production of human papillomavirus capsid protein and virus-like particles
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
US5532133A (en) 1993-06-02 1996-07-02 New York University Plasmodium vivax blood stage antigens, PvESP-1, antibodies, and diagnostic assays
US6106824A (en) 1993-08-13 2000-08-22 The Rockefeller University Expression of growth associated protein B-50/GAP-43 in vitro and in vivo
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
US6033928A (en) 1993-11-02 2000-03-07 Matsushita Electric Industrial Co., Ltd. Method of manufacturing aggregate of semiconductor micro-needles
US5458140A (en) * 1993-11-15 1995-10-17 Non-Invasive Monitoring Company (Nimco) Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers
US5814599A (en) * 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
US5885211A (en) * 1993-11-15 1999-03-23 Spectrix, Inc. Microporation of human skin for monitoring the concentration of an analyte
AU700485B2 (en) 1993-11-17 1999-01-07 Om Pharma Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use
US5693531A (en) 1993-11-24 1997-12-02 The United States Of America As Represented By The Department Of Health And Human Services Vector systems for the generation of adeno-associated virus particles
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5688506A (en) 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
US5457041A (en) 1994-03-25 1995-10-10 Science Applications International Corporation Needle array and method of introducing biological substances into living cells using the needle array
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5591139A (en) 1994-06-06 1997-01-07 The Regents Of The University Of California IC-processed microneedles
CA2560114A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US7037712B2 (en) 1994-07-26 2006-05-02 Commonwealth Scientific And Industrial Research Organisation DNA encoding ovine adenovirus (OAV287) and its use as a viral vector
GB9415319D0 (en) 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
SE9403137D0 (en) 1994-09-20 1994-09-20 Perstorp Ab Derivatives of carbohydrates and compositions containing them
ES2264563T3 (en) 1994-10-07 2007-01-01 Loyola University Of Chicago PARTICLES SIMILAR TO THE PAPILOMA VIRUS, FUSION PROTEINS AND PROCEDURE FOR PREPARATION.
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
FR2727689A1 (en) * 1994-12-01 1996-06-07 Transgene Sa NEW PROCESS FOR THE PREPARATION OF A VIRAL VECTOR
AU4357396A (en) 1995-02-08 1996-08-27 Takara Shuzo Co., Ltd. Cancer control
AU4727296A (en) 1995-02-24 1996-09-11 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
US5912166A (en) 1995-04-21 1999-06-15 Corixa Corporation Compounds and methods for diagnosis of leishmaniasis
UA56132C2 (en) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine
US6846489B1 (en) 1995-04-25 2005-01-25 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
US5718904A (en) * 1995-06-02 1998-02-17 American Home Products Corporation Adjuvants for viral vaccines
US5993800A (en) 1995-06-05 1999-11-30 Bristol-Myers Squibb Company Methods for prolonging the expression of a heterologous gene of interest using soluble CTLA4 molecules and an antiCD40 ligand
US6417172B1 (en) * 1995-06-05 2002-07-09 Eisai Co., Ltd. Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs
US5981215A (en) 1995-06-06 1999-11-09 Human Genome Sciences, Inc. Human criptin growth factor
US6309847B1 (en) 1995-07-05 2001-10-30 Yeda Research And Development Co. Ltd. Method for detecting or monitoring the effectiveness of treatment of T cell mediated diseases
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
AU7254396A (en) 1995-09-29 1997-04-17 Eisai Research Institute Method for treating alcoholic liver disease
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US5618275A (en) 1995-10-27 1997-04-08 Sonex International Corporation Ultrasonic method and apparatus for cosmetic and dermatological applications
US5846758A (en) 1995-11-30 1998-12-08 His Excellency Ghassan I. Shaker Method for diagnosing autoimmune diseases
US5843462A (en) 1995-11-30 1998-12-01 Regents Of The University Of Minnesota Diphtheria toxin epitopes
SE9600648D0 (en) 1996-02-21 1996-02-21 Bror Morein Receptor binding unit
US5656016A (en) 1996-03-18 1997-08-12 Abbott Laboratories Sonophoretic drug delivery system
DK0909562T3 (en) * 1996-07-03 2005-08-22 Eisai Co Ltd Injection preparation containing a lipid A analog and process for its preparation
ATE229073T1 (en) 1996-09-06 2002-12-15 Univ California PROTEIN E25A, METHODS OF ITS PRODUCTION AND APPLICATION
US5955306A (en) 1996-09-17 1999-09-21 Millenium Pharmaceuticals, Inc. Genes encoding proteins that interact with the tub protein
JP4111403B2 (en) 1996-10-11 2008-07-02 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア Immunostimulatory polynucleotide / immunomodulatory molecule complex
JPH10131046A (en) 1996-10-29 1998-05-19 Nikka Chem Co Ltd Durable ph-buffering processing of fiber
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US7033598B2 (en) * 1996-11-19 2006-04-25 Intrabrain International N.V. Methods and apparatus for enhanced and controlled delivery of a biologically active agent into the central nervous system of a mammal
DE19654221B4 (en) 1996-12-23 2005-11-24 Telefonaktiebolaget Lm Ericsson (Publ) Line connection circuit
US5840871A (en) 1997-01-29 1998-11-24 Incyte Pharmaceuticals, Inc. Prostate-associated kallikrein
US6977073B1 (en) 1997-02-07 2005-12-20 Cem Cezayirli Method for stimulating an immune response
AR012035A1 (en) 1997-02-25 2000-09-27 Corixa Corp METHOD FOR DETECTING PROSTATE CANCER, METHOD FOR MONITORING DEVELOPMENT OF PROSTATE CANCER, MONOCLONAL ANTIBODY THAT JOINS A POLYPEPTIDE, AN EFFECTIVE THERAPEUTIC AMOUNT OF MONOCLONAL ANTIBODIES TO PREPARE MEDICINES AND EQUIPMENT FOR
US6541212B2 (en) 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
BR9811262A (en) 1997-04-01 2000-10-17 Ribi Immunochem Research Inc Aqueous immunological auxiliary compositions of monophosphoryl lipid a.
US7037510B2 (en) 1997-04-18 2006-05-02 Statens Serum Institut Hybrids of M. tuberculosis antigens
US6555653B2 (en) 1997-05-20 2003-04-29 Corixa Corporation Compounds for diagnosis of tuberculosis and methods for their use
US6358508B1 (en) * 1997-06-11 2002-03-19 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR9
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
AU7983198A (en) 1997-06-23 1999-01-04 Ludwig Institute For Cancer Research Improved methods for inducing an immune response
CA2297374A1 (en) 1997-07-21 1999-01-28 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
EP2050465B1 (en) 1997-08-29 2014-06-11 Antigenics Inc. Compositions comprising the adjuvant QS-21 and polysorbate or cyclodextrin as excipient
ES2298316T3 (en) 1997-09-05 2008-05-16 Glaxosmithkline Biologicals S.A. WATER OIL EMULSIONS CONTAINING SAPONINS.
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
US6749856B1 (en) 1997-09-11 2004-06-15 The United States Of America, As Represented By The Department Of Health And Human Services Mucosal cytotoxic T lymphocyte responses
US6368604B1 (en) * 1997-09-26 2002-04-09 University Of Maryland Biotechnology Institute Non-pyrogenic derivatives of lipid A
US7459524B1 (en) 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
CN1280619A (en) 1997-11-28 2001-01-17 根瑟特公司 Genomic sequences and polypeptides of chlamydia trachomatis, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infections
US7012134B2 (en) 1998-01-26 2006-03-14 Human Genome Sciences, Inc. Dendritic enriched secreted lymphocyte activation molecule
DE19803453A1 (en) 1998-01-30 1999-08-12 Boehringer Ingelheim Int vaccine
EP1584685B1 (en) 1998-02-05 2011-04-13 GlaxoSmithKline Biologicals SA Tumor-associated antigen derivatives from the mage family, used for the preparation of fusion proteins with T-helper epitopes and of compositions for vaccination
JP2002502884A (en) 1998-02-12 2002-01-29 アメリカン・サイアナミド・カンパニー Vaccine comprising interleukin-12 and herpes simplex virus antigen
US6596501B2 (en) 1998-02-23 2003-07-22 Fred Hutchinson Cancer Research Center Method of diagnosing autoimmune disease
FR2775601B1 (en) * 1998-03-03 2001-09-21 Merial Sas RECOMBINANT LIVING VACCINES AND ADJUVANTS
DE69933200T2 (en) 1998-03-09 2007-02-22 Glaxosmithkline Biologicals S.A. COMBINED VACCINE COMPOSITIONS
CZ302870B6 (en) 1998-04-07 2011-12-28 Corixa Corporation Polynucleotide, polypeptide, pharmaceutical composition, vaccine and their use for the treatment and prevention of tuberculosis infection
GB2336310B (en) 1998-04-14 2003-09-10 Stowic Resources Ltd Method of manufacturing transdermal patches
AU3560399A (en) 1998-04-15 1999-11-01 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
US6680175B2 (en) * 1998-05-05 2004-01-20 Adherex Technologies, Inc. Methods for diagnosing and evaluating cancer
HU225844B1 (en) 1998-05-07 2007-10-29 Corixa Corp Adjuvant composition and its use
US6322532B1 (en) 1998-06-24 2001-11-27 3M Innovative Properties Company Sonophoresis method and apparatus
EP1097208A2 (en) 1998-07-14 2001-05-09 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
AU766994B2 (en) 1998-08-25 2003-10-30 Ronald J. Gallenberg Beach cleaning apparatus and method
EP1111390A4 (en) 1998-09-01 2007-11-14 Eisai R&D Man Co Ltd Method for evaluating lipid a analog-containing injections
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
JP2000095694A (en) * 1998-09-24 2000-04-04 Sankyo Co Ltd New medical drug
US6375944B1 (en) 1998-09-25 2002-04-23 The Wistar Institute Of Anatomy And Biology Methods and compositions for enhancing the immunostimulatory effect of interleukin-12
WO2000018929A2 (en) 1998-09-25 2000-04-06 Smithkline Beecham Biologicals S.A. Paramyxovirus vaccines
US7001770B1 (en) 1998-10-15 2006-02-21 Canji, Inc. Calpain inhibitors and their applications
DE122007000087I1 (en) * 1998-10-16 2008-03-27 Glaxosmithkline Biolog Sa ADJUVANCY SYSTEMS AND VACCINES
US6261573B1 (en) 1998-10-30 2001-07-17 Avant Immunotherapeutics, Inc. Immunoadjuvants
US6734172B2 (en) * 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
US6512102B1 (en) * 1998-12-31 2003-01-28 Chiron Corporation Compositions and methods of diagnosis and treatment using casein kinase I
WO2000042994A2 (en) 1999-01-21 2000-07-27 North Shore-Long Island Jewish Research Institute Inhibition of bacterial dissemination
AU769539B2 (en) * 1999-01-29 2004-01-29 Zoetis Services Llc Adjuvants for use in vaccines
US20030170249A1 (en) 1999-02-19 2003-09-11 Hakomori Sen-Itiroh Vaccines directed to cancer-associated carbohydrate antigens
US6770445B1 (en) 1999-02-26 2004-08-03 Pacific Northwest Research Institute Methods and compositions for diagnosing carcinomas
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
GB9906177D0 (en) 1999-03-17 1999-05-12 Oxford Biomedica Ltd Anti-viral vectors
WO2000062066A1 (en) 1999-04-07 2000-10-19 Hitachi Chemical Co., Ltd. METHOD FOR JUDGING AUTOIMMUNE DISEASE, METHOD FOR DETECTING ANTI-Reg PROTEIN AUTOANTIBODY AND DIAGNOSTICS FOR AUTOIMMUNE DISEASES
CZ303515B6 (en) 1999-04-19 2012-11-07 Smithkline Beecham Biologicals S. A. Adjuvant compositions
US6685699B1 (en) * 1999-06-09 2004-02-03 Spectrx, Inc. Self-removing energy absorbing structure for thermal tissue ablation
EP1206533A1 (en) 1999-08-26 2002-05-22 Pharmacia AB Novel response element
GB9921146D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US7084256B2 (en) 1999-09-24 2006-08-01 Large Scale Biology Corporation Self antigen vaccines for treating B cell lymphomas and other cancers
JP4162813B2 (en) 1999-10-28 2008-10-08 久光製薬株式会社 Iontophoresis device
US6218186B1 (en) 1999-11-12 2001-04-17 Trustees Of The University Of Pennsylvania HIV-MSCV hybrid viral vector for gene transfer
JP2003514824A (en) 1999-11-15 2003-04-22 ビオミラ，インコーポレーテッド Synthetic lipid-A analogs and uses thereof
US20020064801A1 (en) 1999-12-01 2002-05-30 Ryan Jeffrey R. Novel and practical serological assay for the clinical diagnosis of leishmaniasis
US6974588B1 (en) 1999-12-07 2005-12-13 Elan Pharma International Limited Transdermal patch for delivering volatile liquid drugs
US6587792B1 (en) 2000-01-11 2003-07-01 Richard A. Thomas Nuclear packing efficiency
GB0000891D0 (en) 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
US7052904B2 (en) 2000-01-31 2006-05-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Hybrid adeno-retroviral vector for the transfection of cells
EP1122542A1 (en) 2000-02-01 2001-08-08 Anda Biologicals S.A. Method for the rapid detection of whole microorganisms on retaining membranes by use of chaotropic agents
AU2001241738A1 (en) 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
DE60134134D1 (en) 2000-05-19 2008-07-03 Corixa Corp PROPHYLACTIC AND THERAPEUTIC TREATMENT OF TEN WITH COMPOUNDS BASED ON MONOSACCHARIDES
US6875610B2 (en) 2000-05-31 2005-04-05 Human Gene Therapy Research Institute Methods and compositions for efficient gene transfer using transcomplementary vectors
DE10041515A1 (en) 2000-08-24 2002-03-14 Gerold Schuler Process for the production of ready-to-use, antigen-loaded or unloaded, cryopreserved mature dendritic cells
US6969704B1 (en) 2000-08-25 2005-11-29 The Trustees Of Columbia University In The City Of New York Methods for suppressing early growth response—1protein (Egr-1) to reduce vascular injury in a subject
US7060802B1 (en) 2000-09-18 2006-06-13 The Trustees Of Columbia University In The City Of New York Tumor-associated marker
JP2004510746A (en) 2000-10-06 2004-04-08 パラディース，ハー．，ヘンリッヒ Chiver drugs as autoimmune vaccines with immunomodulatory effects
EP1326638B9 (en) 2000-10-18 2008-02-20 GlaxoSmithKline Biologicals S.A. Vaccines against cancers
WO2003004525A2 (en) * 2001-01-26 2003-01-16 Walter Reed Army Institute Of Research Isolation and purification of plasmodium falciparum merozoite protein-142
US6893820B1 (en) 2001-01-31 2005-05-17 The Ohio State University Research Foundation Detection of methylated CpG rich sequences diagnostic for malignant cells
AU2002306896B2 (en) 2001-03-26 2007-04-26 Walter Reed Army Institute Of Research Plasmodium falciparum AMA-1 protein and uses thereof
US7029685B2 (en) 2001-03-26 2006-04-18 The United States Of America As Represented By The Secretary Of The Army Plasmodium falciparum AMA-1 protein and uses thereof
US6933123B2 (en) 2001-04-05 2005-08-23 Yao Xiong Hu Peptides from the E2, E6, and E7 proteins of human papilloma viruses 16 and 18 for detecting and/or diagnosing cervical and other human papillomavirus associated cancers
US6844192B2 (en) * 2001-06-29 2005-01-18 Wake Forest University Adenovirus E4 protein variants for virus production
US7727974B2 (en) * 2001-08-10 2010-06-01 Eisai R & D Management Co., Ltd. Methods of reducing the severity of mucositis
US7078180B2 (en) 2001-09-05 2006-07-18 The Children's Hospital Of Philadelphia Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors
US20040161776A1 (en) 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
US6752995B2 (en) * 2002-04-15 2004-06-22 Board Of Regents, The University Of Texas System Nucleic acid and polypeptide sequences useful as adjuvants
US6908453B2 (en) * 2002-01-15 2005-06-21 3M Innovative Properties Company Microneedle devices and methods of manufacture
US6911434B2 (en) * 2002-02-04 2005-06-28 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
WO2003066065A1 (en) 2002-02-04 2003-08-14 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
RU2288723C2 (en) * 2002-02-04 2006-12-10 Корикса Корпорейшн Preventive and therapeutic method for treating infectious and other diseases by applying immunoeffective compounds
US6676961B1 (en) 2002-03-06 2004-01-13 Automated Carrier Technologies, Inc. Transdermal patch assembly
ATE457733T1 (en) 2002-05-09 2010-03-15 Oncothyreon Inc LIPID A AND OTHER CARBOHYDRATE LIGAND ANALOGS
US7018345B2 (en) 2002-12-06 2006-03-28 Hisamitsu Pharmaceutical Co., Inc. Iontophoresis system
US20050123550A1 (en) * 2003-05-12 2005-06-09 Laurent Philippe E. Molecules enhancing dermal delivery of influenza vaccines
FR2862062B1 (en) 2003-11-06 2005-12-23 Oreal LIPID A AND TOPICAL COMPOSITION, IN PARTICULAR COSMETIC, COMPRISING IT
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
FI2068918T4 (en) * 2006-09-26 2024-08-16 Access To Advanced Health Inst Vaccine composition containing synthetic adjuvant
WO2009035528A2 (en) 2007-09-07 2009-03-19 University Of Georgia Research Foundation, Inc. Synthetic lipid a derivative
PT2437753T (en) 2009-06-05 2016-11-23 Infectious Disease Res Inst Synthetic glucopyranosyl lipid adjuvants and vaccine compositions containing them
WO2013119856A1 (en) 2012-02-07 2013-08-15 Infectious Disease Research Institute Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
JP5328975B2 (en) 2012-12-19 2013-10-30 ルネサスエレクトロニクス株式会社 RF power module
WO2014172637A1 (en) * 2013-04-18 2014-10-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis

Also Published As

Publication number Publication date
IL216669A (en) 2016-04-21
US20140322268A1 (en) 2014-10-30
EP2437753A1 (en) 2012-04-11
US9480740B2 (en) 2016-11-01
ES2606563T3 (en) 2017-03-24
MX2011012836A (en) 2012-04-20
CN102481312B (en) 2015-07-15
JP5830015B2 (en) 2015-12-09
IL216669A0 (en) 2012-02-29
TW201102085A (en) 2011-01-16
EP2437753A4 (en) 2012-12-05
JP2017137327A (en) 2017-08-10
US20100310602A1 (en) 2010-12-09
SMT201600437B (en) 2017-01-10
WO2010141861A1 (en) 2010-12-09
RU2015129468A3 (en) 2019-01-21
US10632191B2 (en) 2020-04-28
JP2016028042A (en) 2016-02-25
TWI549688B (en) 2016-09-21
CN102481312A (en) 2012-05-30
MX360448B (en) 2018-11-01
US8722064B2 (en) 2014-05-13
BRPI1011072A2 (en) 2016-04-12
IL242992B (en) 2018-01-31
CN105131051A (en) 2015-12-09
PT2437753T (en) 2016-11-23
CY1118347T1 (en) 2017-06-28
TW201544120A (en) 2015-12-01
RU2020129844A (en) 2022-03-10
EP2437753B1 (en) 2016-08-31
CA2764374A1 (en) 2010-12-09
MX393384B (en) 2025-03-24
SI2437753T1 (en) 2016-12-30
AU2010256461B2 (en) 2016-03-17
RU2560182C2 (en) 2015-08-20
EP3124491B1 (en) 2019-10-30
TWI494125B (en) 2015-08-01
PL2437753T3 (en) 2017-03-31
DK2437753T3 (en) 2016-12-19
EP3124491A1 (en) 2017-02-01
BRPI1011072B1 (en) 2021-09-28
US20180028649A1 (en) 2018-02-01
HUE031051T2 (en) 2017-06-28
JP6251431B2 (en) 2017-12-20
CN105131051B (en) 2020-07-10
US9814772B2 (en) 2017-11-14
CA2764374C (en) 2019-11-19
JP2012528892A (en) 2012-11-15
LT2437753T (en) 2016-12-12
HRP20161585T1 (en) 2016-12-30
US20170182155A1 (en) 2017-06-29
AU2010256461A1 (en) 2012-01-12
RU2732574C2 (en) 2020-09-21

Similar Documents

Publication Publication Date Title
RU2015129468A (en) SYNTHETIC Glucopyranosyl lipid adjuvants
RU2011152602A (en) SYNTHETIC Glucopyranosyl lipid adjuvants
CN108290845B (en) Pyrimidine compounds
EA200600865A1 (en) ANALOGUES OF C-CLASS OLIGONUCLEOTIDES WITH IMPROVED IMMUNE MULTIRATION EFFICIENCY
RU2018103881A (en) CYCLIC PURINE DINUCLEOTIDES AS STING MODULATORS
JP2012528892A5 (en)
RU2009132006A (en) ANTIBODIES AND THEIR PHARMACEUTICAL COMPOSITIONS SUITABLE FOR INHIBITING THE ACTIVITY OF METALLOPROTEINS
RU2015117251A (en) NEW COMPOUNDS
HRP20110807T1 (en) SUBSTITUTED PIRIMIDODIAZEPINES USEFUL AS PLK1 INHIBITORS
MX2010008468A (en) NUCLEIC ACIDS COMPRISING FORMULA (NuGlX<sub >mGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS.
HRP20050432A2 (en) Novel medicaments for the treatment of chronic obstructive pulmonary diseases
JP2016506916A5 (en)
WO2004064759A3 (en) Use of tryptanthrin compounds for immune potentiation
ES2702337T3 (en) Compound that has a therapeutic effect in immune diseases and use thereof
JP2010537961A5 (en)
EA201291038A1 (en) PYRAZOL COMPOUNDS AS JAK INHIBITORS
JP2015512946A5 (en)
JP2015535831A5 (en)
RU2015116953A (en) New connections
CN114761411A (en) Spiro compound serving as ERK inhibitor and application thereof
RU2011133128A (en) ANTITUMOR COMPOUNDS DIHYDROPIRAN-2-ONA
RU2008137968A (en) IMMUNOMODULATING AND ANTITUMOR PEPTIDES
RU2008128816A (en) ANTITUMEN COMPOUNDS
JP2015529660A5 (en)
EA200300638A1 (en) VACCINE COMPOSITION CONTAINING A TRANSFORMING ALPHA GROWTH FACTOR